Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib

Neoplasia (United States)

Volumn 15, Issue 2, 2013, Pages 143-155

  Walters, Dustin M ^a   Lindberg, James M ^a   Adair, Sara J ^a   Newhook, Timothy E ^a   Cowan, Catharine R ^b   Stokes, Jayme B ^a   Borgman, Cheryl A ^b   Stelow, Edward B ^a   Lowrey, Bryce T ^a   Chopivsky, Maria E ^a   Gilmer, Tona M ^c   Parsons, John T ^b   Bauer, Todd W ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN P16; PROTEIN P53; PROTEIN TYROSINE KINASE; SMAD4 PROTEIN; TRAMETINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84873520791     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121712     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
2. Hidalgo M (2010). Pancreatic cancer. N Engl J Med 362, 1605-1617.
3. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806.
4. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin J.C-H, Leary RJ, Eshleman JR, et al. (2009). SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 15, 4674-4679.
5. Jaffee EM, Hruban RH, Canto M, and Kern SE (2002). Focus on pancreas cancer. Cancer Cell 2, 25-28.
6. Maitra A and Hruban RH (2008). Pancreatic cancer. Annu Rev Pathol 3, 157-188.
7. Shibata D, Capella G, and Perucho M (1990). Mutational activation of the c-K-ras gene in human pancreatic carcinoma. Baillieres Clin Gastroenterol 4, 151-169.
8. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, and Bos JL (1988). KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 16, 7773-7782.
9. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, and Tuveson DA (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483.
10. Lemoine NR (1992). The epidermal growth factor receptor in human pancreatic cancer. J Pathol 166, 7-12.
11. Kimura K, Sawada T, Komatsu M, Inoue M, Muguruma K, Nishihara T, Yamashita Y, Yamada N, Ohira M, and Hirakawa K (2006). Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 12, 4925-4932.
12. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25, 1960-1966.
13. Komoto M, Nakata B, Amano R, Yamada N, Yashiro M, Ohira M, Wakasa K, and Hirakawa K (2009). HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci 100, 1243-1247.
14. Larbouret C, Gaborit N, Chardes T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, and Pelegrin A (2012). In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. Neoplasia 14, 121-130.
15. Poulikakos PI and Solit DB (2011). Resistance to MEK inhibitors: should we co-target upstream? Sci Signal 4, p. e16.
16. Poulikakos PI and Rosen N (2011). Mutant BRAF melanomas-dependence and resistance. Cancer Cell 19, 11-15.
17. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, et al. (2001). The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1, 85-94.
18. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, et al. (2004). A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib). Cancer Res 64, 6652-6659.
19. + hormone receptor-positive metastatic breast cancer. Oncologist 15, 122-129.
20. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J, et al. (2011). GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 17, 989-1000.
21. Yamaguchi T (2011). Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol 39, 23-31.
22. INK4b-inductive compound, as a novel MEK1/2 inhibitor. Cancer Sci 98, 1809-1816.
23. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C, and Goggins M (2007). Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25, 319-325.
24. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, et al. (2012). Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307-321.
25. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, et al. (2009). Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69, 565-572.
26. Stokes JB, Adair SJ, Slack-Davis JK, Walters DM, Tilghman RW, Hershey ED, Lowrey B, Thomas KS, Bouton AH, Hwang RF, et al. (2011). Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther 10, 2135-2145.
27. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, and Fidler IJ (1999). In vivo selection and characterization of metastatic variants from human pancreatic adeno-carcinoma by using orthotopic implantation in nude mice. Neoplasia 1, 50-62.
28. Walters DM, Adair SJ, Stokes JB, Borgman C, Lowrey B, Adams RB, Fox JW, Papin JA, Parsons JT, and Bauer TW (2010). Proceedings of the 101st Annual Meeting of the American Association for Cancer Research-Proceedings Supplement: Late-Breaking Abstracts. AACR, Washington, DC. p. 46 Abstract No. LB-148.
29. Friday BB and Adjei AA (2008). Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14, 342-346.
30. Wang D, Boerner SA, Winkler JD, and LoRusso PM (2007). Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 1773, 1248-1255.
31. Kip1. Cancer Res 65, 4870-4880.
32. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, et al. (2012). Safety, pharmaco-kinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13, 773-781.
33. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, et al. (2012). Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13, 782-789.
34. Harsha HC, Jimeno A, Molina H, Mihalas AB, Goggins MG, Hruban RH, Schulick RD, Kamath U, Maitra A, Hidalgo M, et al. (2008). Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. J Proteome Res 7, 4651-4658.
35. Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio-Viqueira B, Wheelhouse J, Diosdado B, Messersmith WA, Iacobuzio-Donahue C, et al. (2008). Coordinated epidermal growth factor receptor pathway gene over expression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res 68, 2841-2849.
36. Komoto M (2010). In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer. Cancer Sci 101, 468-473.
37. Diep CH, Munoz RM, Choudhary A, Von Hoff DD, and Han H (2011). Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res 17, 2744-2756.